GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed - Release Capsules USP, 20 mg (OTC)12-06-2024
12-06-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Transcript Of Investor Day 2024
The transcript of Investor Day 2024 held on Thursday, May 30, 2024 has been uploaded on Company''s website.04-06-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Audio Recording Of The Glenmark Pharmaceuticals Limited - Investor Day 2024
Audio Recording of Investor Day 2024 held on 30th May, 202431-05-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation
Further to our communication dated 17th May, 2024, attached is the copy of the presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2024 which is scheduled today in Mumbai.30-05-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
The transcript of the Earnings Call held on May 27, 2024 has been uploaded on the Company''s website.29-05-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the financial year 2023-2428-05-2024
Glenmark Pharma Q4 Results Review - Operating Performance Above Estimate; FY25 Outlook Better: Motilal Oswal
Adverse market dynamics/de-prioritisation of intangibles lead to an impairment of Rs 23 billion28-05-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q4 2023-24 Earnings call held on 27th May 2024, on the website of the Company27-05-2024
Glenmark Pharmaceuticals Results Earnings Call for Q4FY24
Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.27-05-2024
Glenmark Pharmaceuticals plans Rs 700 Crores CAPEX in FY25 to boost growth
Glenmark has earmarked Rs 700 crores for consolidated capital expenditures (CAPEX) to bolster its operational infrastructure. This allocation will be used to augment the company's capabilities to meet growing demand efficiently and sustain long-term growth.25-05-2024